aa
atom
absorpt
spectrometri
af
atomicfluoresc
spectrometri
arf
acut
renal
failur
bipp
bismuth
iodoform
paraffin
past
bss
bismuth
subsalicyl
bun
blood
urea
nitrogen
c
difficil
clostridium
difficil
cb
colloid
bismuth
citrat
cddp
cisdiamminedichloroplatinum
dl
detect
limit
dmp
acid
dmsa
dimercaptosuccin
acid
ent
surgeri
ear
nose
throat
surgeri
ep
addit
extremepressur
addit
gsh
glutathion
h
pylori
helicobact
pylori
icpm
induct
coupl
plasma
mass
spectrometri
mbl
metalloblactamas
mic
minimum
inhibitori
concentr
mt
metallothionein
ppibas
proton
pump
inhibitorbas
rbc
ranitidin
bismuth
citrat
aureu
staphylococcu
aureu
sarscov
sever
acut
respiratori
syndrom
coronaviru
bismuth
metal
chemic
element
symbol
bi
atom
number
although
known
sinc
ancient
time
becam
familiar
greek
roman
middl
age
bismuth
often
confus
metal
lead
tin
consid
metal
period
tabl
similar
semimet
bismuth
categor
among
group
element
convent
known
poor
element
due
rariti
use
quit
extens
variou
purpos
includ
cosmet
industri
laboratori
pharmaceut
bismuth
serv
lead
nontox
replac
lead
brass
plumb
fixtur
fish
sinker
free
machin
steel
solder
well
metallurg
addit
foundri
manufactur
applic
bismuth
also
includ
ceram
glaze
pearlesc
pigment
lubric
greas
crystal
ware
major
applic
bismuth
medicin
health
care
relat
high
effect
treat
burn
intestin
disord
stomach
ulcer
well
potenti
activ
microorgan
virus
malign
tumor
develop
new
therapi
better
understand
mechan
action
bismuth
applic
bismuthbas
agent
health
care
extend
bismuth
rel
rare
element
earth
rank
term
natur
abund
earth
crust
estim
ppb
atom
world
reserv
bismuth
usual
estim
base
content
lead
resourc
sinc
bismuth
alway
byproduct
process
metal
ore
lead
silver
tin
copper
zinc
tasna
mine
bolivia
mine
china
produc
bismuth
major
product
world
reserv
bismuth
estim
around
ton
bismuth
consum
rapidli
last
decad
approxim
ton
refineri
bismuth
produc
worldwid
among
countri
china
lead
produc
refin
bismuth
ca
world
total
product
follow
lao
japan
mexico
ca
respect
estim
global
reserv
bismuth
shown
fig
comparison
major
heavi
metal
bismuth
low
toxic
mark
green
metal
environ
bismuth
alloy
widespread
commerci
applic
product
lubric
greas
chemic
catalyst
shot
bullet
cosmet
fire
sprinkler
system
solder
thermoelectr
materi
pigment
fish
sinker
u
u
carrier
medicin
malleabl
steel
etc
semimet
crystal
structur
bismuth
along
physicalchem
properti
expans
solidif
widest
rang
melt
boil
point
among
metal
lowest
thermal
heat
conduct
make
bismuth
ideal
substitut
lead
analog
extremepressur
addit
ep
addit
substitut
formerli
wide
use
leadbas
ep
addit
bismuthsulfur
addit
provid
higher
lubric
efficaci
also
reduc
amount
heavi
metal
use
extremepressur
lubric
half
accord
new
ecolog
environment
philosophi
world
recent
decad
substitut
lead
bismuth
glass
product
may
lead
potenti
applic
bismuth
manufactur
automobil
glass
finest
tablewar
art
object
purpos
environment
protect
north
america
biesn
use
replac
lead
shotshel
hunt
wetland
bird
although
bismuthcontain
shotshel
approv
nontox
comparison
high
toxic
lead
eg
toxic
intak
level
mg
kg
human
higher
toler
bismuth
among
human
eg
toxic
intak
level
mg
kg
human
render
rel
safe
substitut
prevent
environment
problem
caus
lead
accumul
owe
satini
luster
low
absorpt
properti
bismuth
compound
bismuth
oxychlorid
bismuth
vanad
also
use
cosmet
includ
nail
polish
lipstick
eye
shadow
recent
europ
restrict
hazard
substanc
direct
state
lead
must
elimin
manufactur
variou
type
electron
electr
equip
restrict
support
commerci
research
organ
japan
north
america
may
increas
demand
bismuth
industri
futur
acceler
replac
lead
heavi
metal
bismuth
manufactur
industri
medic
use
bismuth
trace
back
year
ago
bismuthrel
agent
involv
treatment
wide
rang
diseas
includ
syphili
sodiumpotassium
bismuth
tartrat
bismuth
quinin
iodid
iododbismitol
bismuth
chlorid
etc
coliti
bismuth
subnitr
bismuth
citrat
wound
infect
bismuth
oxid
parasit
infect
sodium
bismuth
thioglycol
massiv
usag
bismuth
compound
treatment
syphili
wound
infect
earli
centuri
dramat
drop
owe
discoveri
antibiot
thu
contemporari
use
bismuth
medicin
princip
lie
treatment
gastrointestin
disord
gastric
duoden
ulcer
eg
colloid
bismuth
subcitr
cb
bismuth
subsalicyl
bismuth
subnitr
dyspepsia
bismuth
subsalicyl
bismuth
subnitr
etc
diarrhea
bismuth
subsalicyl
bismuth
nitrat
etc
bismuth
subsalicyl
bss
peptobismol
procter
gambl
compani
cincinnati
ohio
unit
state
one
commerci
success
bismuth
medicin
annual
sale
million
usd
unit
state
statist
statist
portal
wide
use
rapid
relief
heartburn
nausea
indigest
diarrhea
basi
crystallograph
analysi
bss
possess
complex
cluster
includ
bi
iii
ion
monodeproton
salicyl
deproton
h
oxo
ligand
upon
interact
gastric
acid
stomach
medicin
releas
bi
iii
ion
known
inhibit
growth
helicobact
pylori
h
pylori
fig
salicyl
amelior
gastriti
antagon
inflamm
bismuth
citratebas
compound
repres
cb
denol
gist
brocad
yamanouchi
typic
antih
pylori
bismuth
drug
wide
util
cocktail
therapi
treat
varieti
h
pyloriassoci
infect
therapeut
efficaci
bismuth
citratebas
drug
h
pyloriassoci
infect
may
attribut
preferenti
format
protect
coat
ulcer
crater
owe
fact
cb
form
polymer
structur
fig
induct
secret
increas
mucos
protect
factor
antimicrobi
activ
bi
iii
attribut
abil
disrupt
multipl
biolog
pathway
via
bind
key
protein
andenzym
ranitidin
bismuth
citrat
rbc
tritec
pylorid
glaxosmithklin
plc
later
found
effici
antiulc
agent
sinc
incorpor
h
receptor
antagonist
ranitidin
suppress
secret
excess
stomach
acid
newli
develop
bismuthbas
tripl
quadrupl
regimen
combin
bismuth
citratebas
drug
antibiot
amoxicillin
tetracyclin
clarithromycin
nitroimidazol
protonpump
inhibitor
ppi
often
recommend
clinic
treat
h
pyloriassoci
infect
comparison
nonbismuth
therapi
bismuthbas
regimen
significantli
increas
erad
rate
antibiot
resist
h
pylori
tabl
even
antibiot
resist
strain
bi
cit
polymer
structur
dimer
unit
bi
cit
polymer
framework
probabl
coat
ulcer
crater
prevent
eros
gastric
acid
neg
charg
bi
cit
framework
balanc
cation
color
code
bi
yellow
c
gray
red
cation
blue
new
drug
bismuth
dpoli
galacturon
acid
colloid
bismuth
pectin
approv
clinic
use
china
treatment
peptic
ulcer
effect
cb
apart
overthecount
bismuth
drug
number
novel
bismuth
compound
remark
antih
pylori
activ
synthes
recent
decad
bi
iii
complex
hydroxam
acid
indolecarboxyl
acid
aamino
acid
nonsteroid
antiinflammatori
acetylsalicyl
acid
glycosaminoglycan
polysaccharid
organ
ligand
exhibit
higher
compar
antih
pylori
activ
bss
cb
sinc
nanotechnolog
extens
explor
bismuthbas
nanomateri
also
receiv
attent
pharmaceut
exampl
bismuth
subcarbon
bio
co
nanotub
exhibit
slightli
higher
activ
h
pylori
clinic
use
colloid
bismuth
subcitr
similar
condit
importantli
bismuth
nanotub
could
use
capsul
bismuthbas
tripl
quadrupl
therapi
treatment
h
pylori
infect
drug
carrier
sustainedreleas
ingredi
human
bodi
use
combin
drug
treatment
diseas
bismuth
effect
antih
pylori
agent
though
appear
bacteriostat
bactericid
differenti
bismuth
organ
antibiot
bismuth
drug
multipl
cellular
target
thu
antih
pylori
action
bismuth
drug
result
comprehens
factor
includ
limit
hindranc
synthesi
bacteri
cell
wall
impedi
bacteri
adhes
inhibit
atp
synthesi
abolish
defens
oxid
stress
ph
buffer
abil
interfer
metal
homeostasi
eg
ni
homeostasi
inhibit
activ
key
enzym
alcohol
dehydrogenas
ureas
dnak
recent
report
show
bismuth
inhibit
ureas
activ
disrupt
cellular
matur
ureas
via
function
perturb
one
accessori
protein
ureg
rather
directli
target
metal
center
ureas
despit
extens
studi
made
molecular
level
exact
mode
action
bismuth
drug
h
pylori
still
remain
unclear
bismuth
also
exhibit
potenti
activ
microorgan
beyond
h
pylori
bismuth
thiolat
one
repres
antimicrobi
agent
among
newli
develop
bismuth
compound
antimicrobi
activ
bismuth
greatli
enhanc
coordin
lipophil
thiolcontain
ligand
bmercaptoethanol
dimercaprol
dithiothreitol
complex
show
antimicrobi
activ
gramneg
bacteri
strain
escherichia
coli
burkholderia
cepacia
complex
klebsiella
pneumonia
well
gramposit
bacteri
strain
staphylococcu
aureu
aureu
streptococcu
pyogen
minimum
inhibitori
concentr
mic
micromolar
level
subsequ
studi
show
bi
iii
thiolat
exhibit
remark
antibiofilm
activ
pseudomona
aeruginosa
methicillinresist
aureu
biofilm
recent
research
indic
antimicrobi
spectrum
bismuth
thiolat
could
broaden
prepar
nanoparticl
form
exemplifi
bisbal
np
enhanc
antimicrobi
potenc
bismuth
thiolat
possibl
part
due
chelat
effect
thiol
significantli
improv
solubl
lipophil
bi
iii
compound
well
rapid
exchang
kinet
labil
thiolat
ligand
insid
bacteri
cell
antimicrobi
activ
bismuth
synergist
enhanc
coordin
antimicrobi
agent
exampl
bismuth
conjug
fluoroquinolon
ie
norfloxacin
ciprofloxacin
show
notabl
activ
mic
micromolar
level
gramposit
andneg
bacteri
strain
e
coli
aureu
epidermidei
e
facecali
b
cereu
b
pumilu
recent
research
reveal
bismuth
compound
drug
could
potenti
use
novel
class
antibiot
adjuv
treatment
infect
caus
metalloblactamas
mbl
produc
superbug
fig
bismuth
drug
ie
colloid
bismuth
subcitr
cb
exhibit
potent
inhibit
mbl
activ
displac
zinc
ion
essenti
cofactor
enzym
activ
site
bismuthbas
antibiot
combin
therapi
greatli
boost
antimicrobi
effect
exist
antibiot
surviv
mice
infect
mbl
superbug
significantli
increas
show
bismuthbas
compound
relat
metallodrug
could
becom
novel
class
mbl
inhibitor
great
potenti
use
effect
antibiot
adjuv
treat
infect
caus
mbl
superbug
wider
clinic
context
bismuth
compound
wide
found
exhibit
potenti
antineoplast
activ
malign
tumor
cell
line
promis
candid
potent
chemotherapeut
activ
bismuth
compound
bismuth
coordin
ligand
includ
thiosemicarbazonethiocarbonohydrazon
hydrazin
dithiocarbam
halid
well
radiosensit
bismuthbas
nanomateri
exampl
bi
iii
complex
bi
h
l
h
l
bi
nmethylthiosemicarbazon
ic
valu
mm
leukemia
cell
inhibitori
rate
hepatocarcinoma
cell
line
xenograft
mous
model
bi
iii
dithiocarbam
complex
gener
formula
bi
exhibit
power
anticanc
activ
seven
cancer
cell
line
includ
breast
cancer
cell
line
ovarian
cancer
cell
line
igrov
ic
valu
mm
watersolubl
bismuth
cyclen
base
compound
abbrevi
bitpc
exhibit
great
anticanc
activ
potent
cisplatin
probabl
via
interact
dna
physiolog
relev
condit
shown
radioact
bismuth
bi
bi
exhibit
promis
potenti
novel
therapeut
agent
mall
volum
tumor
bi
bi
seri
branch
decay
result
emiss
although
halflif
bi
short
h
radioact
lead
pb
h
use
vivo
gener
bi
shortrang
penetr
mm
bismuth
radionuclid
reduc
nonspecif
irradi
normal
tissu
around
target
cell
furthermor
order
deliv
bismuth
site
action
effect
chelat
ligand
use
togeth
bismuth
radionuclid
type
combin
treatment
strong
chelat
ligand
conjug
monoclon
antibodi
fusion
protein
standard
treatment
tumor
via
modif
ligand
eventu
produc
bismuthradiolabel
complex
metal
radiolabel
complex
introduc
host
target
specif
cell
type
site
diseas
releas
aparticl
near
tumor
tissu
therebi
minim
damag
surround
normal
tissu
recent
chemic
conjug
abbrevi
tambi
mp
np
incorpor
bismuth
sulfid
mesopor
silica
coreshel
nanoparticl
trastuzumab
antibodi
target
overexpress
breast
cancer
cell
ration
design
exert
good
anticanc
activ
good
biocompat
drug
load
abil
conjug
reach
certain
degre
direct
target
higher
bismuth
content
target
tumor
group
compar
nontarget
group
type
bibas
nanomateri
may
pioneer
new
direct
develop
targetdirect
therapeut
agent
cancer
treatment
antitumor
mechan
action
bi
iii
compound
princip
correl
gener
ro
reduct
mitochondri
membran
potenti
induct
apoptosi
via
mediat
arrest
mechan
rather
dna
bind
platinum
compound
carri
though
bismuthdna
bind
sporad
report
uniqu
mode
action
bi
iii
base
anticanc
agent
display
great
potenti
circumv
therapeut
stress
place
upward
cisplatin
resist
detail
mechan
action
bibas
anticanc
agent
still
remain
mysteri
explor
mechanist
therapeut
level
bismuth
compound
anticanc
agent
might
serv
new
direct
futur
report
antivir
applic
bismuth
compound
except
bismuth
sodium
triglycollam
histor
use
treat
wart
recent
bismuth
discov
effect
inhibit
sever
acut
respiratori
syndrom
coronaviru
sarscov
ic
less
mm
potenti
target
bismuth
scv
ntpasehelicas
zinccontain
enzym
rna
cap
activ
control
viru
reproduct
bind
bismuth
may
induc
conform
chang
enzym
subsequ
affect
helicas
rnadna
unwind
activ
therebi
inhibit
viru
prolifer
fig
anoth
potenti
applic
bismuth
compound
amelior
side
effect
induc
anticanc
drug
cisplatin
cisplatin
analog
eg
carboplatin
oxaliplatin
use
clinic
worldwid
treat
variou
solid
cancer
howev
major
obstacl
widespread
use
cisplatinbas
drug
resid
sever
side
effect
major
doselimit
factor
nephrotox
includ
tubular
degener
loss
brush
border
necrosi
miner
tubular
epitheli
cell
renal
damag
caus
platinum
pt
mechan
platinum
nephrotox
may
similar
mercuri
hg
like
relat
deplet
thiolat
group
renal
tube
bismuth
compound
bismuth
sub
nitrat
report
allevi
cisplatininduc
nephrotox
without
interf
antitumor
respons
recent
studi
show
bismuthcitr
base
complex
bizn
significantli
preserv
renal
function
mice
receiv
overdos
cisplatin
treatment
compound
could
potenti
simul
product
antioxid
biomolecul
metallothionein
glutathion
kidney
cell
minim
cisplatininduc
apoptosi
vivo
experi
display
compar
cisplatinalon
group
group
mice
receiv
pretreat
bismuth
compound
greatli
reduc
blood
urea
nitrogen
bun
creatinin
level
defin
indic
renal
damag
surviv
rate
significantli
increas
fig
unlik
heavi
metal
eg
lead
mercuri
bismuth
relat
drug
involv
clinic
treatment
h
pyloriassoci
infect
decad
seldom
report
acut
toxic
human
even
administ
extrem
dosag
case
long
period
time
remain
mysteri
bismuth
iii
select
toxic
certain
human
pathogen
rather
human
be
one
possibl
reason
limit
gastrointestin
tract
git
absorpt
bismuth
oral
administr
recent
studi
indic
glutathion
gsh
may
play
vital
role
bismuth
metabol
detoxif
mammalian
cell
bismuth
ion
found
passiv
absorb
conjug
gsh
transport
vesicl
via
mrp
transport
sequestr
absorb
bismuth
consum
cytosol
glutathion
activ
de
novo
biosynthesi
turn
facilit
passiv
uptak
bismuth
fig
selfpropel
posit
feedback
cycl
activ
elimin
bismuth
intraand
extracellular
space
thu
protect
critic
system
human
bodi
acut
toxic
consid
gsh
ubiquit
live
cell
absent
certain
anaerob
microanaerob
bacteria
h
pylori
gsh
mrp
mediat
selfpropel
dispos
bismuth
host
cell
might
account
select
toxic
bismuth
drug
biolog
system
protein
enzym
regard
potenti
target
bismuth
investig
bismuthprotein
interact
improv
understand
mechan
action
bismuth
also
provid
basi
design
effect
bismuth
agent
bismuth
found
bind
transferrin
iron
transport
protein
preferenti
clobe
carbon
co
synergist
anion
transferrin
like
act
bismuth
transport
vehicl
satur
iron
blood
plasma
importantli
metalbound
transferrin
rapidli
recogn
transferrin
receptor
higher
affin
receptor
metalbound
transferrin
apoform
fig
although
human
serum
albumin
abund
protein
serum
mm
hypothes
target
bismuth
plasma
around
bismuth
associ
transferrin
rest
increas
bismuth
concentr
serum
albumin
indic
higher
select
bismuth
transferrin
lactoferrin
anoth
type
major
iron
bind
protein
transferrin
famili
also
strongli
bind
bismuth
ion
bismuthbound
lactoferrin
abl
compet
ironbound
lactoferrin
membran
intracellular
provid
anoth
rout
bismuth
transport
histidinerich
protein
hpn
hpnlike
histidin
residu
respect
h
pylori
also
potenti
target
bismuth
ion
mutagenesi
experi
shown
h
pylori
hpn
gene
knockout
fourfold
suscept
bismuth
antiulc
drug
wildtyp
indic
protect
role
hpn
h
pylori
respons
bismuthbas
therapi
interact
bismuth
enzym
relat
high
affin
cystein
residu
exampl
bismuth
inhibit
ureas
activ
probabl
block
enzym
activ
site
coordin
cystein
residu
entranc
activ
site
although
bismuth
consid
nontox
state
previous
longterm
use
bismuth
may
result
certain
degre
side
effect
human
subject
besid
case
caus
occup
exposur
bismuth
manufactur
industri
poison
incid
occur
form
accident
deliber
overdosag
bismuth
drug
extent
bismuth
toxic
depend
individu
case
ie
type
bismuth
compound
amount
absorb
still
clear
select
individu
develop
bismuth
toxic
patient
suffer
toxic
differ
bismuth
level
blood
syndrom
rare
bismuth
level
mgl
among
bismuthbas
regimen
use
insolubl
bismuth
compound
bismuth
oxychlorid
bismuth
subcarbon
relat
low
toxic
wherea
use
solubl
bismuth
organ
compound
bismuth
sodium
tartrat
tripotassium
dicitratobismuth
combin
use
bismuth
thiolatecontain
ligand
associ
high
toxic
neurotox
nephrotox
probabl
due
enhanc
uptak
solubl
bismuth
salt
human
bodi
also
suggest
oral
bismuth
drug
need
undergo
methyl
intestin
microb
enabl
absorb
absorb
bismuth
accumul
kidney
lung
spleen
liver
brain
muscl
elimin
urin
fece
via
bile
intestin
secret
clinic
depend
administr
time
bismuth
toxic
roughli
divid
acut
chronic
exposur
exposur
dose
caus
neurotox
gastrointestin
toxic
nephrotox
hepatotox
increas
bismuth
concentr
blood
spite
toxic
side
effect
allevi
discontinu
bismuth
therapi
bismuth
iodoform
paraffin
past
bipp
reduc
risk
bacteri
infect
render
deep
necrot
wound
caviti
clean
promot
develop
granul
tissu
wide
use
oral
maxillofaci
ent
surgeri
ear
nose
throat
surgeri
antisept
dress
howev
exampl
seriou
advers
effect
bipp
observ
clinic
patient
treat
bipp
one
case
patient
becam
acut
confus
gait
becam
unsteadi
indic
encephalopathi
caus
overdosag
bismuth
confirm
observ
toxic
level
bismuth
patient
serum
anoth
case
involv
use
bipp
cover
dura
mater
wound
remov
larg
basal
cell
carcinoma
patient
becam
confus
comatos
encephalopathi
confirm
observ
diffus
cerebr
edema
tomograph
scan
howev
upon
remov
bipp
patient
recov
deterior
pack
appli
mechan
intox
well
understood
till
probabl
caus
interfer
bismuth
oxid
metabol
central
nervou
system
bind
essenti
enzym
reduc
cerebr
blood
flow
case
nephrotox
overdosag
cb
one
case
even
gastric
lavag
perform
initi
boy
suffer
acut
renal
failur
arf
associ
uremia
oliguria
ingest
denol
tablet
cb
g
day
ingest
cb
day
bismuth
level
blood
urin
mgl
respect
treatment
periton
dialysi
urin
volum
increas
plasma
bun
creatinin
level
decreas
gradual
day
admiss
patient
recov
bismuth
level
blood
went
back
normal
cure
seriou
side
effect
caus
bismuth
overdosag
antidot
dpenicillamin
acid
dmp
dimercaptosuccin
acid
dmsa
dimercaprol
test
anim
limit
clinic
trial
shown
dmp
dmsa
effect
allevi
bismuth
poison
due
strong
chelat
abil
bismuth
ion
read
